Stock Evaluator: Scribe Therapeutics Inc. (SCTX)

Scribe Therapeutics Inc. SCTX

$15.74 -0.03 -0.19%
November 18, 2026 1:41:56 PM EST November 10, 2021 Volume: 102,294
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.

Commentary & Analysis


Financial Summary

Share Statistics SCTX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $299.4 $208.2 33%
Shares Out (Mil) 14.5 55.4 26%
Institutional Ownership 69.4% 92.9% 42%
Float (Mil) 6.4 40.7 15%
Beta na 1.00 na
Avg Daily Volume (000s) 322 570 50%
Price Change
(52-week)
na 40.7% na
Growth SCTX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) na (10.3%) na
EPS (5yr) na 15.5% na
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) na (15.7%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 1 3
Current EPS ($0.285) ($2.250) ($3.387)
Month Ago EPS ($1.060) ($5.590) ($3.617)
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS ($0.983) ($5.925) ($3.443)
Year/Year Chg (58.1%) (74.9%) (53.5%)
Financials SCTX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $15 $39 11%
Net Income (TTM) (Mil) ($44) ($44) 17%
EPS (TTM) ($7.932) ($1.400) 5%
Operating Cash Flow (TTM) (Mil) ($38) ($34) 11%
Net Cash Flow (TTM) (Mil) $153 $-0 81%
Long-Term Debt (Q1) (Mil) $4 $4 23%
Enterprise Value (Q1) (Mil) $141 $138 24%
Valuation SCTX Industry
Median
Percentile
(All Stocks)
P/B 2.39 1.96 62%
P/E na 17.7 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.8 na
Ratios SCTX Industry
Median
Percentile
(All Stocks)
Gross Margin (202.8%) 67.9% 1%
Net Margin (294.4%) (50.8%) 4%
ROA (46.4%) (47.4%) 12%
ROE (69.7%) (51.6%) 12%
Liabilities to Assets 33.4% 29.7% 24%
F-Score 1 3 na

Scribe Therapeutics Inc. did not pass any screens on 11/17/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors